Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Ed Hurwitz
AddedMar 31, 2024
UpdatedMay 31, 2026
Ed Hurwitz

Ed Hurwitz

Board Member, MacroGenics

Crunchbase

Ed Hurwitz's Career

MacroGenics
MacroGenics

Rockville, MD, US

Board Member· Board
ViewPoint Therapeutics
ViewPoint Therapeutics

San Francisco, CA, US

Board Member· Board
ReCode Therapeutics
ReCode Therapeutics

Menlo Park, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Ed Hurwitz's Career

MacroGenics
MacroGenics
Public$165.9M3572000Rockville, MD, US
Board Member· Board

Leadership at MacroGenics

Kenneth GalbraithKenneth GalbraithBoard Member
Bill HeidenBill HeidenBoard Member
Scott KoenigScott KoenigBoard Member
Jeff BuchalterJeff BuchalterBoard Member
David StumpDavid StumpBoard Member
Jeffrey V. RavetchJeffrey V. RavetchFounder

Similar to MacroGenics

Kyntra BioKyntra BioSan Francisco, CA, USPharmaceuticalsest. 1993Kyntra BioSan Francisco, CA, US · est. 1993

FibroGen, Inc: A global, research-based pharmaceutical company in San Francisco, innovating treatments for unmet medical needs.

Public · $188M592
IgenicaIgenicaBurlingame, CA, USBiopharmaceuticalsest. 2008IgenicaBurlingame, CA, US · est. 2008

Igenica, Inc.: A biotherapeutics firm creating monoclonal antibodies for cancer treatment in the US.

Pre-Seed · $80.6M11
ViewPoint Therapeutics
ViewPoint Therapeutics

San Francisco, CA, US

Board Member· Board
ReCode Therapeutics
ReCode Therapeutics
Series B$521.8M1432015Menlo Park, CA, US
Board Member· Board

Leadership at ReCode Therapeutics

Michael Torres, PhDMichael Torres, PhDCo-Founder
Daniel SiegwartDaniel SiegwartCo-Founder
Shehnaaz SulimanShehnaaz SulimanBoard Member
Rana Al-HallaqRana Al-HallaqBoard Member
Alan ColowickAlan ColowickBoard Member

Similar to ReCode Therapeutics

Artan BioArtan BioSt. Petersburg, FL, USArtan BioSt. Petersburg, FL, US

Artan Bio develops engineered transfer RNA therapies that target mutation-driven aging biology.

Seed · $1M
Code BiotherapeuticsCode BiotherapeuticsHatfield, PA, USGene Therapyest. 2020Code BiotherapeuticsHatfield, PA, US · est. 2020

Code Biotherapeutics: Pioneering non-viral gene therapies for serious genetic diseases.

Series A · $85M47
Encoded TherapeuticsEncoded TherapeuticsSouth San Francisco, CA, USPrecision Therapiesest. 2014Encoded TherapeuticsSouth San Francisco, CA, US · est. 2014

Encoded: Leveraging human genome power for effective precision therapies in genetic disorders.

Series D · $239.1M200
Recursion PharmaceuticalsRecursion PharmaceuticalsSalt Lake City, UT, USPharmaceuticalsest. 2013Recursion PharmaceuticalsSalt Lake City, UT, US · est. 2013

Recursion Pharmaceuticals: An American company innovating hereditary disease treatments.

Public · $665.4M500

Ed Hurwitz's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoSean JohSean JohBoard Member · Kakao

People Similar to Ed Hurwitz

Luke EvninLuke EvninBoard Member · DigiTx PartnersTodd FoleyTodd FoleyBoard Member · Tetherex PharmaceuticalsRobert HuginRobert HuginBoard Member · CelgeneWoody MarshallWoody MarshallBoard Member · Payoneer GlobalJack L. WyszomierskiJack L. WyszomierskiBoard Member · AthersysJay HoagJay HoagBoard Member · Tripadvisor